PAQ Therapeutics
PAQ Therapeutics to Present First Clinical Data for PT0253, a Selective KRAS G12D Degrader, in Late-Breaking Oral Presentation at the 2026 EORTC-NCI-AACR Symposium
Presentation to highlight the initial safety profile and antitumor activity of PT0253 in advanced solid tumors, including in patients who received…